<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004259</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-9813</org_study_id>
    <secondary_id>CDR0000067512</secondary_id>
    <secondary_id>ECOG-R9813</secondary_id>
    <secondary_id>NCCTG-RTOG-9813</secondary_id>
    <nct_id>NCT00004259</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas</brief_title>
  <official_title>A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in
      chemotherapy, such as temozolomide, carmustine, and lomustine, use different ways to stop
      tumor cells from dividing so they stop growing or die. Combining radiation therapy with
      chemotherapy may kill more tumor cells.

      PURPOSE: This randomized phase III trial is studying radiation therapy and temozolomide to
      see how well they work compared to radiation therapy and carmustine or lomustine in treating
      patients with anaplastic astrocytoma or mixed gliomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the overall survival and time to tumor progression in patients with anaplastic
           astrocytoma or mixed gliomas treated with radiotherapy combined with temozolomide vs
           carmustine or lomustine vs temozolomide and carmustine (arm discontinued as of 8/15/02).

        -  Compare the relative toxic effects of these regimens in these patients.

        -  Correlate molecular analyses with overall survival and time to tumor progression in
           patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age
      (under 50 vs 50 and over), Karnofsky performance status (60-80% vs 90-100%), and prior
      surgery (biopsy only vs resection).

      Phase I

        -  Pilot Arms I and II: Prior to initiating the randomization to 1 of 3 treatment arms in
           phase III, Patients are accrued to Arm III regimen to determine tolerability.

      Phase III

        -  Patients are randomized to 1 of 2 treatment arms (3rd arm was dropped).

             -  Arm I: Patients undergo radiotherapy 5 days a week for 6 weeks. Patients receive
                oral temozolomide on days 1-5 of the first week of radiotherapy. Chemotherapy
                repeats every 4 weeks for a total of 12 courses.

             -  Arm II: Patients undergo radiotherapy as in arm I. Patients receive carmustine IV
                or lomustine IV over 1-2 hours on days 1-3 of the first week of radiotherapy and a
                second course on days 56-58. Chemotherapy repeats every 8 weeks for a total of 6
                courses.

             -  Arm III (dropped, did not open): Patients undergo radiotherapy as in arm I.
                Patients receive carmustine IV or lomustine IV over 3 hours on day 5 and oral
                temozolomide (2 hours after completion of carmustine or lomustine infusion) on days
                1-5 of the first week of radiotherapy. Combination chemotherapy repeats every 8
                weeks for 6 courses.

      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: Phase I: 30 patients; Phase III: 454 patients (227 per treatment arm)
      within 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase I (sequential) followed by phase III (parallel)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Phase III) Overall Survival (OS)</measure>
    <time_frame>From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.</time_frame>
    <description>Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Per the protocol, the pilot arms were not included in the Phase III analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Phase I) Number of Subjects With Dose Limiting Toxicities (DLT) on the Two Pilot Arms</measure>
    <time_frame>From start of treatment to 3 months</time_frame>
    <description>Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the adverse event (AE). The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Dose limiting toxicity (DLT) was defined as grade 3+ pulmonary toxicity, grade 4+ thrombocytopenia (&lt; 25,000 for 5 days), neutropenia (&lt; 500/microl for 7 days), or neutropenia of any duration with fever requiring hospital admission after one dose reduction of 50% in BCNU. A 20% rate of grade 3+ pulmonary toxicities or a 40% rate of grade 4+ thrombocytopenia and neutropenia was considered unacceptable for a treatment arm combining RT, TMZ, and BCNU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Phase III) Time to Tumor Progression (TTP)</measure>
    <time_frame>From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.</time_frame>
    <description>Three-year rate is reported. Progression is defined as a radiographic increase in size of the lesion by &gt; 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Time to tumor progression was estimated using the cumulative incidence function (CIF) on tumor progression, with death as a competing risk. Per the protocol, the pilot arms were not included in the Phase III analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase III) Number of Patients With Grade 3 or Higher Toxicity</measure>
    <time_frame>From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.</time_frame>
    <description>Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the AE. The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. The number of patients with grade or higher toxicity was calculated overall and for non-hematologic toxicity only. Per the protocol, the pilot arms were not included in the Phase III analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase III) Correlation of Molecular Analyses With Overall Survival and Time to Tumor Progression</measure>
    <time_frame>From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Radiation therapy + temozolomide (TMZ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT + BCNU/CCNU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilot Arm #1: RT+TMZ+BCNU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 200mg/m2 and TMZ 150mg/m2 six 6-week cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilot Arm #2: RT+TMZ+BCNU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 150mg/m2 and TMZ 150mg/m2 six 8-week cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCNU 80mg/m2</intervention_name>
    <description>BCNU 80 mg/m2 will be administered as an intravenous infusion on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58, then every eight weeks for four more cycles for a total of 6 cycles (maximum BCNU dose 1440 mg/m2).</description>
    <arm_group_label>RT + BCNU/CCNU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMZ 200mg/m2</intervention_name>
    <description>200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.</description>
    <arm_group_label>Radiation therapy + temozolomide (TMZ)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.</description>
    <arm_group_label>Radiation therapy + temozolomide (TMZ)</arm_group_label>
    <arm_group_label>RT + BCNU/CCNU</arm_group_label>
    <arm_group_label>Pilot Arm #1: RT+TMZ+BCNU</arm_group_label>
    <arm_group_label>Pilot Arm #2: RT+TMZ+BCNU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCNU</intervention_name>
    <description>CCNU at 130 mg/m2 orally every 8 weeks for a total of 6 cycles. Administered on day 1 of the first week of radiotherapy and on day 56, then administered every 8 weeks for four more cycles for a total of 6 cycles.</description>
    <arm_group_label>RT + BCNU/CCNU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCNU 150mg/m2</intervention_name>
    <description>BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).</description>
    <arm_group_label>Pilot Arm #2: RT+TMZ+BCNU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCNU 200mg/m2</intervention_name>
    <description>BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).</description>
    <arm_group_label>Pilot Arm #1: RT+TMZ+BCNU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMZ 150mg/m2 six 6-week cycles</intervention_name>
    <description>150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles</description>
    <arm_group_label>Pilot Arm #1: RT+TMZ+BCNU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMZ 150mg/m2 six 8-week cycles</intervention_name>
    <description>150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles</description>
    <arm_group_label>Pilot Arm #2: RT+TMZ+BCNU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven unifocal anaplastic astrocytoma or mixed gliomas, including the
             following:

               -  Anaplastic astrocytoma

               -  Mixed oligodendroglial/astrocytic tumors

                    -  Oligodendroglial component must be no greater than 25%

          -  No vascular proliferation and necrosis

          -  Increased cellularity, pleomorphism, and nuclear atypia allowed

          -  No tumor predominantly located in the posterior fossa (i.e., brainstem or cerebellum)

          -  Patients with prior biopsy proven low grade astrocytoma who now have anaplastic
             astrocytoma and have had no prior radiotherapy or chemotherapy also eligible

          -  Study therapy must begin within 6 weeks of diagnosis

          -  No spinal cord tumors, spinal drop metastases, or metastases to noncontiguous meninges

               -  Pathologic evidence of local meningeal infiltration by underlying tumor allowed

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  At least 1 year

        Hematopoietic:

          -  Hemoglobin at least 10 g/dL

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 150,000/mm^3

        Hepatic:

          -  Bilirubin less than 2 times upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) less than 2 times ULN

          -  Alkaline phosphatase less than 2 times ULN

        Renal:

          -  Blood urea nitrogen no greater than 25 mg/dL

          -  Creatinine less than 1.5 times normal

        Pulmonary:

          -  No pre-existing lung disease that, in the investigator's opinion, would preclude
             administration of carmustine or lomustine or completion of therapy

        Other:

          -  No other major medical illness or psychiatric impairment that would preclude study
             compliance

          -  No other malignancy within the past 5 years except nonmelanomatous skin cancer or
             carcinoma in situ of the cervix

          -  No known hypersensitivity to 1 of the components of carmustine, lomustine,
             temozolomide, dacarbazine, or any other nitrosourea

          -  No active infection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior biologic therapy

        Chemotherapy:

          -  See Disease Characteristics

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy to brain or head and neck

        Surgery:

          -  Not specified

        Other:

          -  No other concurrent anticancer treatment for anaplastic astrocytoma until a recurrence
             is detected
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M. Chang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt A. Jaeckle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Bushunow, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lipson Cancer and Blood Center at Rochester General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mobile Infirmary Medical Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36652-2144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Services Foundation</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enloe Cancer Center at Enloe Medical Center</name>
      <address>
        <city>Chico</city>
        <state>California</state>
        <zip>95926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Cancer Center</name>
      <address>
        <city>Fairfield</city>
        <state>California</state>
        <zip>94533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solano Radiation Oncology Center</name>
      <address>
        <city>Vacaville</city>
        <state>California</state>
        <zip>95687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Regional Cancer Center at Boca Raton Community Hospital - Main Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Oncology Associates at Southside Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center South</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Oncology Associates</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Center - Palatka</name>
      <address>
        <city>Palatka</city>
        <state>Florida</state>
        <zip>32177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flagler Cancer Center</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute at University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John B. Amos Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graham Hospital</name>
      <address>
        <city>Canton</city>
        <state>Illinois</state>
        <zip>61520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>Carthage</city>
        <state>Illinois</state>
        <zip>62321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eureka Community Hospital</name>
      <address>
        <city>Eureka</city>
        <state>Illinois</state>
        <zip>61530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galesburg Clinic</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galesburg Cottage Hospital</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InterCommunity Cancer Center of Western Illinois</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mason District Hospital</name>
      <address>
        <city>Havana</city>
        <state>Illinois</state>
        <zip>62644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopedale Medical Complex</name>
      <address>
        <city>Hopedale</city>
        <state>Illinois</state>
        <zip>61747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kewanee Hospital</name>
      <address>
        <city>Kewanee</city>
        <state>Illinois</state>
        <zip>61443</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McDonough District Hospital</name>
      <address>
        <city>Macomb</city>
        <state>Illinois</state>
        <zip>61455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BroMenn Regional Medical Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of Central Illinois, PC - Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Center at Pekin Hospital</name>
      <address>
        <city>Pekin</city>
        <state>Illinois</state>
        <zip>61554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Proctor Hospital</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Illinois Oncology Research Association</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of Central Illinois, PC - Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Medical Center of Illinois</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Valley Community Hospital</name>
      <address>
        <city>Peru</city>
        <state>Illinois</state>
        <zip>61354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perry Memorial Hospital</name>
      <address>
        <city>Princeton</city>
        <state>Illinois</state>
        <zip>61356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Margaret's Hospital</name>
      <address>
        <city>Spring Valley</city>
        <state>Illinois</state>
        <zip>61362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Cancer Center</name>
      <address>
        <city>Spring Valley</city>
        <state>Illinois</state>
        <zip>61362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic, PC</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Chanute</name>
      <address>
        <city>Chanute</city>
        <state>Kansas</state>
        <zip>66720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Dodge City</name>
      <address>
        <city>Dodge City</city>
        <state>Kansas</state>
        <zip>67801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - El Dorado</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Kingman</name>
      <address>
        <city>Kingman</city>
        <state>Kansas</state>
        <zip>67068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Medical Center</name>
      <address>
        <city>Liberal</city>
        <state>Kansas</state>
        <zip>67901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Newton</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Parsons</name>
      <address>
        <city>Parsons</city>
        <state>Kansas</state>
        <zip>67357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Pratt</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Salina</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Cancer Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Wellington</name>
      <address>
        <city>Wellington</city>
        <state>Kansas</state>
        <zip>67152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Womens Health, PA - North Review</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Medical Arts Tower</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Cancer Center at Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Winfield</name>
      <address>
        <city>Winfield</city>
        <state>Kansas</state>
        <zip>67156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Health Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Montana Cancer Consortium</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Billings Clinic - Downtown</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Cancer Center at Good Samaritan Hospital</name>
      <address>
        <city>Kearney</city>
        <state>Nebraska</state>
        <zip>68848-1990</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center at Methodist Hospital - Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin &amp; Edith Scarpa Regional Cancer Center at South Jersey Healthcare</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Virtua Health Cancer Program at Virtua West Jersey</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipson Cancer and Blood Center at Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospitals - Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44309-2090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles M. Barrett Cancer Center at University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK Medical Oncology Unit at Churchill Hospital &amp; Weatherall Institute of Molecular Medicine - Oxford</name>
      <address>
        <city>Salem</city>
        <state>Ohio</state>
        <zip>44460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Center</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natalie Warren Bryant Cancer Center at St. Francis Hospital</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center at Thomas Jefferson University - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Cancer Center at Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19612-6052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Cancer Center at Guthrie Clinic Sayre</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latter Day Saints Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theda Care Cancer Institute</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital Regional Cancer Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Cancer Care Center at Bay Area Medical Center</name>
      <address>
        <city>Marinette</city>
        <state>Wisconsin</state>
        <zip>54143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Memorial Hospital Cancer Care Center</name>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <zip>53051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconcin Cancer Center at Aspirus Wausau Hospital</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <results_reference>
    <citation>Chang SM, Seiferheld W, Curran W, Share R, Atkins J, Choucair A, Kresl J, Thoron L, Cairncross G, Gilbert M, Bahary JP, Dolinskas C, Louis DN, Bushunow P, Buckner J, Barger G, Mehta M. Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1122-6.</citation>
    <PMID>15234047</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>May 25, 2017</results_first_submitted>
  <results_first_submitted_qc>October 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2017</results_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Radiation Therapy + Temozolomide (TMZ)</title>
          <description>Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles</description>
        </group>
        <group group_id="P2">
          <title>RT + BCNU/CCNU</title>
          <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles</description>
        </group>
        <group group_id="P3">
          <title>Pilot Arm #1: RT+TMZ+BCNU</title>
          <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 200mg/m2 and TMZ 150mg/m2 six 6-week cycles</description>
        </group>
        <group group_id="P4">
          <title>Pilot Arm #2: RT+TMZ+BCNU</title>
          <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 150mg/m2 and TMZ 150mg/m2 six 8-week cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible patients</population>
      <group_list>
        <group group_id="B1">
          <title>Radiation Therapy + Temozolomide (TMZ)</title>
          <description>Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles</description>
        </group>
        <group group_id="B2">
          <title>RT + BCNU/CCNU</title>
          <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles</description>
        </group>
        <group group_id="B3">
          <title>Pilot Arm #1: RT+TMZ+BCNU</title>
          <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 200mg/m2 and TMZ 150mg/m2 six 6-week cycles</description>
        </group>
        <group group_id="B4">
          <title>Pilot Arm #2: RT+TMZ+BCNU</title>
          <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 150mg/m2 and TMZ 150mg/m2 six 8-week cycles</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="225"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="18" upper_limit="73"/>
                    <measurement group_id="B2" value="43" lower_limit="19" upper_limit="80"/>
                    <measurement group_id="B3" value="48" lower_limit="26" upper_limit="80"/>
                    <measurement group_id="B4" value="41" lower_limit="25" upper_limit="74"/>
                    <measurement group_id="B5" value="43" lower_limit="18" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>(Phase III) Overall Survival (OS)</title>
        <description>Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Per the protocol, the pilot arms were not included in the Phase III analyses.</description>
        <time_frame>From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.</time_frame>
        <population>Eligible randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Radiation Therapy + Temozolomide (TMZ)</title>
            <description>Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles</description>
          </group>
          <group group_id="O2">
            <title>RT + BCNU/CCNU</title>
            <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase III) Overall Survival (OS)</title>
          <description>Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Per the protocol, the pilot arms were not included in the Phase III analyses.</description>
          <population>Eligible randomized patients</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="3.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.2" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesized median survival time was 36 months for the RT+BCNU/CCNU arm and 54 months for the RT+TMZ arm, corresponding to a hazard ratio (HR) of 0.67. A sample size of 216 evaluable patients per arm would provide 90% power with a one-sided significance level of 0.05. The final analysis was planned after 155 deaths were observed. Interim efficacy analyses were planned after 52 and 104 deaths, with an interim futility analysis planned at 128 deaths.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Phase I) Number of Subjects With Dose Limiting Toxicities (DLT) on the Two Pilot Arms</title>
        <description>Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the adverse event (AE). The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Dose limiting toxicity (DLT) was defined as grade 3+ pulmonary toxicity, grade 4+ thrombocytopenia (&lt; 25,000 for 5 days), neutropenia (&lt; 500/microl for 7 days), or neutropenia of any duration with fever requiring hospital admission after one dose reduction of 50% in BCNU. A 20% rate of grade 3+ pulmonary toxicities or a 40% rate of grade 4+ thrombocytopenia and neutropenia was considered unacceptable for a treatment arm combining RT, TMZ, and BCNU.</description>
        <time_frame>From start of treatment to 3 months</time_frame>
        <population>Eligible patients who started study treatment on Pilot Arms 1 and 2</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Arm #1: RT+TMZ+BCNU</title>
            <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 200mg/m2 and TMZ 150mg/m2 six 6-week cycles</description>
          </group>
          <group group_id="O2">
            <title>Pilot Arm #2: RT+TMZ+BCNU</title>
            <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 150mg/m2 and TMZ 150mg/m2 six 8-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase I) Number of Subjects With Dose Limiting Toxicities (DLT) on the Two Pilot Arms</title>
          <description>Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the adverse event (AE). The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Dose limiting toxicity (DLT) was defined as grade 3+ pulmonary toxicity, grade 4+ thrombocytopenia (&lt; 25,000 for 5 days), neutropenia (&lt; 500/microl for 7 days), or neutropenia of any duration with fever requiring hospital admission after one dose reduction of 50% in BCNU. A 20% rate of grade 3+ pulmonary toxicities or a 40% rate of grade 4+ thrombocytopenia and neutropenia was considered unacceptable for a treatment arm combining RT, TMZ, and BCNU.</description>
          <population>Eligible patients who started study treatment on Pilot Arms 1 and 2</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with Pulmonary DLT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Hematologic DLT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase III) Time to Tumor Progression (TTP)</title>
        <description>Three-year rate is reported. Progression is defined as a radiographic increase in size of the lesion by &gt; 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Time to tumor progression was estimated using the cumulative incidence function (CIF) on tumor progression, with death as a competing risk. Per the protocol, the pilot arms were not included in the Phase III analyses.</description>
        <time_frame>From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.</time_frame>
        <population>Eligible randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Radiation Therapy + Temozolomide (TMZ)</title>
            <description>Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles</description>
          </group>
          <group group_id="O2">
            <title>RT + BCNU/CCNU</title>
            <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase III) Time to Tumor Progression (TTP)</title>
          <description>Three-year rate is reported. Progression is defined as a radiographic increase in size of the lesion by &gt; 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Time to tumor progression was estimated using the cumulative incidence function (CIF) on tumor progression, with death as a competing risk. Per the protocol, the pilot arms were not included in the Phase III analyses.</description>
          <population>Eligible randomized patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" lower_limit="35.2" upper_limit="55.0"/>
                    <measurement group_id="O2" value="54.7" lower_limit="44.2" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>2-sided</p_value_desc>
            <method>Gray's test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>Reference level = RT + BCNU/CCNU</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase III) Number of Patients With Grade 3 or Higher Toxicity</title>
        <description>Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the AE. The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. The number of patients with grade or higher toxicity was calculated overall and for non-hematologic toxicity only. Per the protocol, the pilot arms were not included in the Phase III analyses.</description>
        <time_frame>From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.</time_frame>
        <population>Eligible randomized patients who started study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Radiation Therapy + Temozolomide (TMZ)</title>
            <description>Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles</description>
          </group>
          <group group_id="O2">
            <title>RT + BCNU/CCNU</title>
            <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase III) Number of Patients With Grade 3 or Higher Toxicity</title>
          <description>Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the AE. The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. The number of patients with grade or higher toxicity was calculated overall and for non-hematologic toxicity only. Per the protocol, the pilot arms were not included in the Phase III analyses.</description>
          <population>Eligible randomized patients who started study treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-hematologic toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall toxicity</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>2-sided</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-hematologic toxicity</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <p_value_desc>2-sided</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase III) Correlation of Molecular Analyses With Overall Survival and Time to Tumor Progression</title>
        <time_frame>From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.</time_frame>
        <posting_date>09/2019</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Eligible subjects who started study treatment and have toxicity information are included. Subjects experiencing more than one of a given adverse event are counted only once for that adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Radiation Therapy + Temozolomide (TMZ)</title>
          <description>Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles</description>
        </group>
        <group group_id="E2">
          <title>RT + BCNU/CCNU</title>
          <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles</description>
        </group>
        <group group_id="E3">
          <title>Pilot Arm #1: RT+TMZ+BCNU</title>
          <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 200mg/m2 and TMZ 150mg/m2 six 6-week cycles</description>
        </group>
        <group group_id="E4">
          <title>Pilot Arm #2: RT+TMZ+BCNU</title>
          <description>Radiation therapy for 6 weeks concurrent with and followed by BCNU 150mg/m2 and TMZ 150mg/m2 six 8-week cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Packed red blood cell transfusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet transfusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis externa (exc boil of meatus) NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Otitis media serous NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="RTOG/EORTC Late Tox.">Late RT Toxicity:Eye NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptons-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="RTOG/EORTC Late Tox.">Late RT Toxicity:Other NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infection with grade 3 or 4 neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infection, Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bilirbin-graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukopenia NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes for BMT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pulmonary function test NOS decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperglycemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ataxia NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Convulsions NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness (exc vertigo)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="RTOG/EORTC Late Tox.">Late RT Toxicity:Brain NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Speech disorder NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vertigo NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnea NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pulmonary-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Culture wound positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thrombosis NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic-Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hearing-Other</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea NOS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Esophagitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="RTOG/EORTC Late Tox.">Late RT Toxicity:Other NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="RTOG/EORTC Late Tox.">Late RT Toxicity:Skin(within RT field)NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase NOS increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukopenia NOS</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Metabolic-Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pulmonary function test NOS decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperglycemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Muscle weakness NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia NEC</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ataxia NEC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Convulsions NOS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness (exc vertigo)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache NOS</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="RTOG/EORTC Late Tox.">Late RT Toxicity:Brain NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Learning disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Speech disorder NEC</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tremor NEC</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety NEC</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depression NEC</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia NEC</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnea NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative NOS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dermatitis radiation NOS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site reaction NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Skin-Other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Accrual to the TMZ BCNU arm required an acceptable toxicity profile from a pilot arm. Treatment cessation/reduction for toxicity caused the combination arm to be dropped. Per the protocol, the pilot arms were not included in the Phase III analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Wendy Seiferheld, M.S.</name_or_title>
      <organization>NRG Oncology</organization>
      <email>seiferheldw@nrgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

